Taysha Gene Therapies (NASDAQ:TSHA – Get Free Report) is set to release its earnings data after the market closes on Tuesday, May 14th. Analysts expect Taysha Gene Therapies to post earnings of ($0.11) per share for the quarter.
Taysha Gene Therapies (NASDAQ:TSHA – Get Free Report) last released its quarterly earnings results on Tuesday, March 19th. The company reported $0.35 earnings per share for the quarter. The company had revenue of $3.60 million for the quarter, compared to analyst estimates of $4.75 million. On average, analysts expect Taysha Gene Therapies to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Taysha Gene Therapies Stock Down 4.0 %
Shares of NASDAQ:TSHA opened at $2.38 on Wednesday. The firm has a market cap of $445.11 million, a PE ratio of -3.70 and a beta of 0.37. The company has a fifty day simple moving average of $2.66 and a 200 day simple moving average of $2.10. The company has a current ratio of 4.08, a quick ratio of 4.08 and a debt-to-equity ratio of 0.54. Taysha Gene Therapies has a 12-month low of $0.50 and a 12-month high of $3.89.
Analyst Ratings Changes
Check Out Our Latest Analysis on Taysha Gene Therapies
Taysha Gene Therapies Company Profile
Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.
See Also
- Five stocks we like better than Taysha Gene Therapies
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- How to Read an Earnings Report | Step by Step Guide with Tips
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Datadog: In the Doghouse or Pullback to the Buyzone?
- 3 Warren Buffett Stocks to Buy Now
- Celsius Stock’s Post-Earnings Morning Dip, Better than Coffee
Receive News & Ratings for Taysha Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taysha Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.